HBK Investments’s Achillion Pharmaceuticals ACHN Stock Holding History

HBK Investments’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-42,900	Closed	-$121K	–	1427
2018 Q2	$121K	Buy	+42,900	New	+$146K	﹤0.01%	980
2018 Q1	–	Sell	-14,300	Closed	-$41K	–	1211
2017 Q4	$41K	Buy	+14,300	New	+$52K	﹤0.01%	950
2017 Q2	–	Sell	-62,863	Closed	-$265K	–	1067
2017 Q1	$265K	Sell	62,863 -539,326	-90%	-$2.24M	﹤0.01%	594
2016 Q4	$2.49M	Buy	602,189 +226,589	+60%	+$1.2M	0.02%	300
2016 Q3	$3.04M	Buy	375,600 +247,500	+193%	+$2.1M	0.03%	288
2016 Q2	$999K	Buy	128,100 +69,100	+117%	+$593K	0.01%	572
2016 Q1	$455K	Buy	+59,000	New	+$432K	﹤0.01%	751
2015 Q2	–	Sell	-116,106	Closed	-$1.15M	–	1164
2015 Q1	$1.15M	Buy	+116,106	New	+$1.45M	0.01%	534
2014 Q4	–	Sell	-207,100	Closed	-$2.07M	–	1182
2014 Q3	$2.07M	Buy	+207,100	New	+$1.92M	0.03%	373
2013 Q3	–	Sell	-79,700	Closed	-$652K	–	996
2013 Q2	$652K	Buy	+79,700	New	+$608K	0.01%	507

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

HBK Investments's ACHN Position: Q3 2018 in Review

HBK Investments sold out of Achillion Pharmaceuticals (ACHN) in Q3 2018, closing a stake of 42,900 shares — an estimated $121K sold.

HBK Investments first reported a position in ACHN in Q2 2013 and held it in 10 quarters. The position peaked at $3.04M in Q3 2016. 137 funds tracked by Wall St. Rank hold ACHN as of Q3 2018.

HBK Investments reported no remaining Achillion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
HBK Investments sold 42,900 Achillion Pharmaceuticals shares in Q3 2018, an estimated $121K.
HBK Investments first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
HBK Investments's Achillion Pharmaceuticals position peaked at $3.04M in Q3 2016.
137 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2018.

Based on HBK Investments's 13F filing for Q3 2018, filed 14 Nov 2018.